Open mobile menu
Model.SiteSettings!.GetInTouchLink!.Name Contact Us
Jroberts Jruaux Dpingstone 03 B012378 CROPPED
Insights

News

Stay up to date with news about Secerna and intellectual property topics.

VENCLEXTA®

A to Z: Drugs in Highlight: V is for VENCLEXTA®

News A to Z Feature 30/04/2025

Our A to Z series highlights VENCLEXTA® (venetoclax) from AbbVie, a medication used to treat both chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). This article explores its mechanism of action, clinical applications, and the patent protection surrounding this important drug.

Read more
EPO 2021
European, Industry news 01/11/2022

Plausibility at the EPO - G2/21

B012799
Events 16/10/2022

Oncology & Precision Medicine Conferences 2022

News234
Industry news 14/10/2022

Pushing the boundaries of scientific discovery

News232
European 05/10/2022

Patenting Antibodies at the European Patent Office

News231
Team news 27/09/2022

Biotech specialist joins growing Yorkshire IP law firm

News230
Events 05/09/2022

Secerna to attend Medical Technology Ireland conference

Hazel R With Scarf Sept 22
Team news, Careers 23/08/2022

Hazel Robson in profile

News228
Industry news 08/08/2022

EPO Board of Appeal confirms safety and efficacy are implicit to medical treatment claims

News227
Team news 28/07/2022

New appointment for Secerna in York

18 19 20 21 22 23 24 25 26 27 28